NERV says roluperidone phase III trial is on track; results due next year
NERV is advancing roluperidone for negative symptoms of schizophrenia with a confirmatory phase III trial underway. Results are expected in the second half of next year.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.